Phase 2 Study of AMG 386 Plus Paclitaxel With or Without Bevacizumab as First Line Therapy in Her2-Negative Breast Cancer Patients
NCT ID: NCT00511459
Last Updated: 2015-10-29
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
228 participants
INTERVENTIONAL
2007-07-31
2014-05-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
AMG 386 is a man-made medication that is designed to stop the development of blood vessels in cancer tissues. Cancer tissues rely on the development of new blood vessels, a process called angiogenesis, to obtain a supply of oxygen and nutrients to grow.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Safety Study of AMG 386 to Treat HER2-positive Locally Recurrent or Metastatic Breast Cancer
NCT00807859
A Trial of 2 Schedules of Ixabepilone Plus Bevacizumab and Paclitaxel Plus Bevacizumab for Breast Cancer
NCT00370552
Paclitaxel Plus Monoclonal Antibody Therapy in Treating Women With Recurrent or Metastatic Breast Cancer
NCT00003539
Study Evaluating the Safety and Efficacy of Onartuzumab And/or Bevacizumab in Combination With Paclitaxel in Participants With Metastatic, Triple Negative Breast Cancer
NCT01186991
Paclitaxel With or Without Bevacizumab in Treating Patients With Locally Recurrent or Metastatic Breast Cancer
NCT00028990
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Secondary Objective(s):
* To compare the treatment effect as measured by PFS of subjects receiving open-label AMG 386 in combination with paclitaxel relative to paclitaxel + bevacizumab + placebo
* To compare the treatment effect as measured by PFS of subjects receiving AMG 386 in combination with paclitaxel and bevacizumab relative to paclitaxel + AMG 386
* To evaluate the safety and tolerability of the combination and non-bevacizumab regimens
* To estimate other measures (RR, DOR, TTR, TTP) of treatment effect
* To evaluate the pharmacokinetics (PK) of AMG 386 and bevacizumab when used in combination
* To estimate the incidence of anti-AMG386 antibody formation
Exploratory Objective(s):
* To explore the pharmacodynamic (PD) response as assessed by changes in blood levels of angiogenic cytokines, tumor apoptosis, and other markers
* To explore the association of histological features and selected immunologic, biochemical, pharmacogenetic, or angiogenic markers in tumor biopsies, plasma, or serum samples with safety and/or efficacy outcomes
Study Design:
This is a phase 2, randomized, placebo controlled, multi-center study to estimate the treatment effect and evaluate the safety and tolerability of AMG 386 in combination with paclitaxel and paclitaxel/bevacizumab in the treatment of subjects with Her2-negative metastatic or locally recurrent breast cancer.
Two hundred twenty subjects will be randomized 1:1:1:1 to each of the following arms:
Arm A: Paclitaxel 90 mg/m² IV QW (3 on/1 off) + bevacizumab 10 mg/kg IV Q2W + AMG 386 10 mg/kg IV QW Arm B: Paclitaxel 90 mg/m² IV QW (3 on/1 off) + bevacizumab 10 mg/kg IV Q2W + AMG 386 3 mg/kg IV QW Arm C: Paclitaxel 90 mg/m² IV QW (3 on/1 off) + bevacizumab 10 mg/kg IV Q2W + AMG 386 placebo IV QW Arm D: Paclitaxel 90 mg/m² IV QW (3 on/1 off) + Open Label AMG 386 10 mg/kg IV QW To maintain the double-blind in arms A, B, and C, each subject will be infused weekly with a volume of investigational product equivalent to 10 mg/kg AMG 386 IV. Arm D will receive open label AMG 386 and will not receive a placebo for bevacizumab.
Subjects will be discontinued from study treatment at any time for radiographic disease progression, clinical progression, unacceptable toxicity, subject withdrawal of consent, or death.
Subjects alive at the time of discontinuation of all study medications will be followed for up to 48 months from the date of the last subject enrolled into the trial to evaluate overall survival.
Radiological imaging to assess disease status will be performed every 8 weeks ± 7 days (2 cycles) for 2 years and then every 4 months ± 1 month thereafter during the study until subjects develop radiographic disease progression per the modified RECIST criteria. In addition, any subject who discontinues study drug treatment prior to disease progression will continue to have radiological imaging performed every 8 weeks ± 7 days during the long term follow up period if the subject has not been in the study for 2 years until the subject develops radiographic disease progression or begins a new treatment. If the subject has been on study for 2 years, radiological imaging every 4 months ± 1 month will be performed during long term follow-up period until the subject develops radiographic disease progression or begins a new treatment.
The overall study design is described by a study schema immediately following this synopsis. Amgen Global Safety (AGS) will charter a data review team (DRT) that is independent of the team conducting the study and will review unblinded safety data after 20, 40, and 80 subjects have been randomized and have had the opportunity to receive at least 1 cycle (4 weeks) of study treatment.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
A
Paclitaxel 90 mg/m² IV QW (3 on/1 off) + bevacizumab 10 mg/kg IV Q2W + AMG 386 10 mg/kg IV QW
Bevacizumab
Bevacizumab 10mg/kg IV Q2W
AMG 386
AMG 386 10mg/kg IV QW \[blinded\]
Paclitaxel
Paclitaxel 90mg/m2 IV QW (3 on/1 0ff)
D
Paclitaxel 90 mg/m² IV QW (3 on/1 off) + Open Label AMG 386 10 mg/kg IV QW
AMG 386
AMG 386 10mg/kg IV QW \[Open-Label\]
Paclitaxel
Paclitaxel 90mg/m2 IV QW (3 on/1 0ff)
B
Paclitaxel 90 mg/m² IV QW (3 on/1 off) + bevacizumab 10 mg/kg IV Q2W + AMG 386 3 mg/kg IV QW
AMG 386
AMG 386 3mg/kg IV QW \[blinded\]
Bevacizumab
Bevacizumab 10mg/kg IV Q2W
Paclitaxel
Paclitaxel 90mg/m2 IV QW (3 on/1 0ff)
C
Paclitaxel 90 mg/m² IV QW (3 on/1 off) + bevacizumab 10 mg/kg IV Q2W + AMG 386 placebo IV QW
AMG 386 Placebo
AMG 386 Placebo \[blinded\]
Bevacizumab
Bevacizumab 10mg/kg IV Q2W
Paclitaxel
Paclitaxel 90mg/m2 IV QW (3 on/1 0ff)
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
AMG 386 Placebo
AMG 386 Placebo \[blinded\]
AMG 386
AMG 386 3mg/kg IV QW \[blinded\]
Bevacizumab
Bevacizumab 10mg/kg IV Q2W
AMG 386
AMG 386 10mg/kg IV QW \[Open-Label\]
AMG 386
AMG 386 10mg/kg IV QW \[blinded\]
Paclitaxel
Paclitaxel 90mg/m2 IV QW (3 on/1 0ff)
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Measurable or non-measurable disease per modified RECIST guidelines
* ECOG of 0 or 1 (within 14 days prior to randomization)
* Adequate organ and hematological function as evidenced by the following laboratory studies within 14 days prior to randomization:
• Cardiac function, as follows:
* Normal sinus rhythm (no significant ECG changes)
* Left ventricular ejection fraction ≥ LLN, as determined by echocardiogram or MUGA scan, according to institutional standards within 28 days prior to randomization
Exclusion Criteria
* Common Terminology Criteria for Adverse Events (CTCAE) Version 3.0 peripheral neuropathy \> grade 1 at randomization
* History of arterial or venous thrombosis, including transient ischemic attack (TIA), within 1 year prior to randomization
* Adjuvant or neoadjuvant taxane treatment within 12 months of randomization. Any other adjuvant chemotherapy regimen must be discontinued at least 21 days prior to randomization
* Prior chemotherapy, vaccine, or biological therapy for locally recurrent or metastatic breast cancer (prior endocrine therapy is permitted)
* Prior radiation therapy, radiofrequency ablation, percutaneous cryotherapy or hepatic chemoembolization on all sites of disease unless disease progression was subsequently documented 14 days prior to randomization.
* Overexpression of HER-2 (gene amplification by FISH or 3+ over expression by immunohistochemistry).
* Current or prior history of central nervous system metastasis
* History of bleeding diathesis or clinically significant bleeding within 6 months prior to randomization
* Major surgical procedure within 28 days prior to randomization
* Open breast biopsy within 14 days prior to randomization
* Minor surgical procedure, placement of access device, or fine needle aspiration within 7 days of first dose
* Prior malignancy (other than thyroid cancer, in situ cervical cancer, or basal cell cancer of the skin, treated with curative intent and without evidence of disease for ≥ 3 years prior to randomization)
* Clinically significant cardiac disease within 12 months prior to randomization, including myocardial infarction, unstable angina, grade 2 or greater peripheral vascular disease, cerebrovascular accident, transient ischemic attack, congestive heart failure, or arrhythmias not controlled by outpatient medication
* Non-healing wound, ulcer or fracture
* Known hypersensitivity to paclitaxel or drugs using the vehicle cremophor
* Known hypersensitivity to bacterial proteins, or any of the drugs required in this study
* Known positive test for human immunodeficiency virus (HIV), hepatitis C, or hepatitis B surface antigen
* Known active or chronic hepatitis
* Uncontrolled hypertension as defined as systolic blood pressure ≥ 150 mm Hg and diastolic blood pressure ≥ 90 mm Hg. Anti-hypertensive medications are allowed if the subject is stable on their current dose at the time of randomization
* Currently or previously treated with any VEGF or VEGFr inhibitor, including but not limited to, bevacizumab, SU11248 (sunitinib), PTK787 (vatalinib), AZD 2171, AEE-788, BAY 43-9006 (sorafenib) and AMG 706.
* Treatment with coumarin-type anticoagulants, (other than low dose prophylaxis for central venous catheters ≤ 1mg/day) within 7 days prior to randomization
* Currently or previously treated with angiopoietin inhibitors, or inhibitors of TIE-1 or TIE-2 including, but not limited to, AMG 386, XL880, XL820
* Treatment with immune modulators such as cyclosporine and tacrolimus within 30 days prior to randomization
* Concomitant therapy with any hormonal agent such as raloxifene, tamoxifen, or other selective estrogen receptor modulators (SERMS), given for breast cancer prevention or for osteoporosis. Subjects must have discontinued these agents 28 days prior to randomization
* Pregnant (ie, positive beta-human chorionic gonadotropin test) or is breast feeding
18 Years
FEMALE
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Amgen
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
MD
Role: STUDY_DIRECTOR
Amgen
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Research Site
Litchfield Park, Arizona, United States
Research Site
Tucson, Arizona, United States
Research Site
Hot Springs, Arkansas, United States
Research Site
Little Rock, Arkansas, United States
Research Site
Campbell, California, United States
Research Site
Los Angeles, California, United States
Research Site
Murrieta, California, United States
Research Site
Santa Maria, California, United States
Research Site
New Haven, Connecticut, United States
Research Site
Stamford, Connecticut, United States
Research Site
Orlando, Florida, United States
Research Site
Robbinsdale, Minnesota, United States
Research Site
Henderson, Nevada, United States
Research Site
Lebanon, New Hampshire, United States
Research Site
Nashua, New Hampshire, United States
Research Site
Edison, New Jersey, United States
Research Site
Mountain Lakes, New Jersey, United States
Research Site
Asheville, North Carolina, United States
Research Site
Charlotte, North Carolina, United States
Research Site
Hershey, Pennsylvania, United States
Research Site
Philadelphia, Pennsylvania, United States
Research Site
Columbia, South Carolina, United States
Research Site
Richardson, Texas, United States
Research Site
San Antonio, Texas, United States
Research Site
Sugar Land, Texas, United States
Research Site
Ogden, Utah, United States
Research Site
Kurralta Park, South Australia, Australia
Research Site
Epping, Victoria, Australia
Research Site
Fitzroy, Victoria, Australia
Research Site
Footscray, Victoria, Australia
Research Site
Malvern, Victoria, Australia
Research Site
Perth, Western Australia, Australia
Research Site
Innsbruck, , Austria
Research Site
Vienna, , Austria
Research Site
Wels, , Austria
Research Site
Leuven, , Belgium
Research Site
Liège, , Belgium
Research Site
Wilrijk, , Belgium
Research Site
Herlev, , Denmark
Research Site
Helsinki, , Finland
Research Site
La Roche-sur-Yon, , France
Research Site
Lyon, , France
Research Site
Marseille, , France
Research Site
Montpellier, , France
Research Site
Paris, , France
Research Site
Paris, , France
Research Site
Toulouse, , France
Research Site
Vandœuvre-lès-Nancy, , France
Research Site
Gyula, , Hungary
Research Site
Kaposvár, , Hungary
Research Site
Szombathely, , Hungary
Research Site
Veszprém, , Hungary
Research Site
Bangalore, Karnataka, India
Research Site
Miraj, Maharashtra, India
Research Site
Mumbai, Maharashtra, India
Research Site
Nagpur, Maharashtra, India
Research Site
Pune, Maharashtra, India
Research Site
Jaipur, Rajasthan, India
Research Site
Jaipur, Rajasthan, India
Research Site
Maastricht, , Netherlands
Research Site
Gdansk, , Poland
Research Site
Lubin, , Poland
Research Site
Poznan, , Poland
Research Site
Warsaw, , Poland
Research Site
Warsaw, , Poland
Research Site
Wroclaw, , Poland
Research Site
Jaén, AndalucÃ-a, Spain
Research Site
Sabadell, Cataluña, Spain
Research Site
Santiago de Compostela, Galicia, Spain
Research Site
Madrid, Madrid, Spain
Research Site
Guildford, , United Kingdom
Research Site
Leicester, , United Kingdom
Research Site
London, , United Kingdom
Research Site
London, , United Kingdom
Research Site
Manchester, , United Kingdom
Research Site
Northwood, , United Kingdom
Research Site
Nottingham, , United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Dieras V, Wildiers H, Jassem J, Dirix LY, Guastalla JP, Bono P, Hurvitz SA, Goncalves A, Romieu G, Limentani SA, Jerusalem G, Lakshmaiah KC, Roche H, Sanchez-Rovira P, Pienkowski T, Segui Palmer MA, Li A, Sun YN, Pickett CA, Slamon DJ. Trebananib (AMG 386) plus weekly paclitaxel with or without bevacizumab as first-line therapy for HER2-negative locally recurrent or metastatic breast cancer: A phase 2 randomized study. Breast. 2015 Jun;24(3):182-90. doi: 10.1016/j.breast.2014.11.003. Epub 2015 Mar 5.
Related Links
Access external resources that provide additional context or updates about the study.
AmgenTrials clinical trials website
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
20060341
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.